尖峰集团：JFAN-1001甲磺酸盐胶囊获得药物临床试验批准

Core Viewpoint - The company has received approval for a clinical trial of its new anti-tumor drug, JFAN-1001, which targets advanced non-squamous non-small cell lung cancer patients with specific genetic mutations [1] Group 1: Company Developments - Zhejiang Jianfeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Jianfeng Group, has received a clinical trial approval notice from the National Medical Products Administration for JFAN-1001 mesylate capsules [1] - The clinical trial will evaluate the combination of JFAN-1001 with Tarceva (erlotinib) soft capsules in patients with advanced non-squamous non-small cell lung cancer [1] - JFAN-1001 is classified as a Class 1 chemical drug and is indicated for locally advanced or metastatic non-small cell lung cancer with EGFR-T790M secondary mutations [1] Group 2: Clinical Trial Status - The clinical trial application for JFAN-1001 was accepted on September 8, 2025, and is currently undergoing Phase II clinical trials in China [1] - The drug has also received clinical trial permission from the U.S. Food and Drug Administration [1]